×
-0.000901171522979695 -0.000450585761489954 -0.000750976269149852 -0.00420546710723943 -0.00638329828777406 -0.00750976269149895 -0.00841093421447864 -0.00555722439170908
Stock impact report

AbbVie abandons late-stage lung cancer asset Rova-T [Reuters]

AbbVie, Inc (ABBV)  More Company Research Source: Reuters
Last abbvie, inc earnings: 7/26 07:42 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF AbbVie abandons late-stage lung cancer asset Rova-T - Reuters 2 Min Read (Reuters) - AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage trial for a type of lung cancer. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, but recorded impairment charges of about $4 billion in January after it halted enrolment of a separate study testing the therapy. An independent data monitoring committee recommended terminating the trial after an interim data analysis, the company said on Thursday. Rova-T is a drug-antibody combination that targets a protein called DLL3, found in over 80% of patients with small-cell lung cancer. AbbVie, which is testing treatments for more than 20 different types of cancer, said it will now prioritize other development programs within its cancer pipeline. The drugmaker in June said it would acquire Allergan Plc for about $63 billion [Read more]
Impact snapshot Event time: ABBV
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ABBV alerts

from News Quantified
Opt-in for
ABBV alerts

from News Quantified